# **Topical Collection**

## Coronaviruses

## Message from the Collection Editors

Human coronaviruses (HCoVs), including NL63, 229E, OC43, and HKU1, are responsible for seasonal mild respiratory illness. However, two HCoVs (SARS and MERS) have been shown to cause severe morbidity and mortality in humans. Recently (December 2019) a novel HCoV, Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2), was identified in the city of Wuhan in China, and has been responsible for the COVID-19 pandemic with an alarming case fatality, posing an unprecedented threat to human health and economy. To date, no United States Food and Drug Administration (FDA)-approved vaccines and/or specific antivirals are available for the treatment of SARS-CoV-2 infection in humans, which has triggered vast scientific efforts to develop countermeasures to deal with SARS-CoV-2 infection.

In this Topical Collection about coronavirus, we aim to cover all the aspects related to coronavirus disease, including virus—host interactions, viral pathogenesis, animal models, antivirals, vaccine development, immunity, prophylactics, therapeutics, and reverse genetics.

### **Collection Editors**

Prof. Dr. Luis Martinez-Sobrido

Disease Prevention and Intervention Program, Texas Biomedical Research Institute, San Antonio, TX, USA

Dr. Fernando Almazan Toral

Department of Molecular and Cell Biology, National Center for Biotechnology, Darwin 3, 28049 Madrid, Spain



## Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/55172

Viruses Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 viruses@mdpi.com

mdpi.com/journal/ viruses





# Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

#### **Editor-in-Chief**

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

#### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

## **Journal Rank:**

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

